In this issue:
Vemurafenib + rituximab in R/R HCL
Copanlisib + rituximab in relapsed indolent NHL
Eprenetapopt + azacitidine in TP53-mutated MDS/AML
Real-world data for tisagenlecleucel in R/R large B-cell lymphoma
Adverse events in CML treated with TKIs
Second cancers after treatment of childhood NHL
Loncastuximab tesirine in R/R B-cell NHL
Auto vs allo SCT in poor-risk peripheral T-NHL
Obinutuzumab vs rituximab for advanced DLBCL
MRD monitoring by NGS at 2 time points after AML chemo
Please login below to download this issue (PDF)